SELLAS Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid Leukemia - SELLAS Life Sciences Gr (NASDAQ:SLS)
– SLS009 Is First CDK9 Inhibitor in Combination with AZA/VEN to Achieve Complete Response in AML Patient Resistant to Venetoclax Combination Therapies – – First Patient Enrolled Achieved CR and in Fifth Month of
Source: benzinga.com